Plasma Total Cholesterol Level as a Risk Factor for Alzheimer Disease: The Framingham Study
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Previous studies examining the association of plasma cholesterol levels with the risk for development of Alzheimer disease (AD) have been inconclusive. We examined the impact of baseline and lifetime plasma total cholesterol levels averaged across many years on the risk for AD in a large, population-based cohort. METHODS: Five thousand two hundred nine subjects from the Framingham Study original cohort underwent biennial evaluation for cardiovascular risk factors since 1950, with estimations of serum total cholesterol levels at 19 of these 25 biennial examinations. The study sample consisted of 1026 subjects from this cohort who were alive and free of stroke and dementia at examination cycle 20 (1988-1989) and had undergone apolipoprotein E (APOE) genotyping. The main outcome measure was incident AD diagnosed using standard criteria, according to average total cholesterol levels across biennial examination cycles 1 to 15 and baseline total cholesterol level measured at the 20th biennial examination cycle. RESULTS: Alzheimer disease developed in 77 subjects from 1992 to 2000. After adjustment for age, sex, APOE genotype, smoking, body mass index (calculated as weight in kilograms divided by the square of height in meters), coronary heart disease, and diabetes, we found no significant association between the risk for incident AD and average cholesterol level at biennial examination cycles 1 to 15 (hazard ratio per 10-mg/dL [0.3-mmol/L] rise, 0.95; 95% confidence interval, 0.87-1.04) or baseline total cholesterol level at examination 20 (hazard ratio, 0.97; 95% confidence interval, 0.90-1.05). CONCLUSION: In this large, population-based cohort, baseline and long-term average serum total cholesterol levels were not associated with the risk for incident AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429 · cited 1×
“T HE APOLIPOPROTEIN E (APOE) 4 allele is a cholesterol transport protein that is a well-established risk factor for late-onset Alzheimer disease (AD).(1) The presence of an APOE 4 allele increases the lifetime risk for development of AD and is also associated with an earlier age of onset.”
BackgroundAbell, L. L., Levy, B. B., Brodie, B. B., & Kendall, F. E. (1952) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)50907-3 · Cited by 3,086
Warnick, G. R., Benderson, J., & Albers, J. J. (1982) · Clinical Chemistry · doi:10.1093/clinchem/28.6.1379 · Cited by 2,159
Statins and the risk of dementia
Jick, H., Zornberg, G., Jick, S., Seshadri, S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,759
Self-citationWolozin, B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.10.1439 · Cited by 1,398
Current Perspectives on Statins
Maron, D. J., Fazio, S., & Linton, M. F. (2000) · Circulation · doi:10.1161/01.cir.101.2.207 · Cited by 1,213
Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons
Simons, M., Keller, P., De Strooper, B., Beyreuther, K., Dotti, C. G., & Simons, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6460 · Cited by 1,166
Hofman, A., Ott, A., Breteler, M. M., Bots, M. L., Slooter, A. J., van Harskamp, F., van Duijn, C. N., Van Broeckhoven, C., & Grobbee, D. E. (1997) · The Lancet · doi:10.1016/s0140-6736(96)09328-2 · Cited by 1,062
Cited by
Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention
Qiu, C., Kivipelto, M., & von Strauss, E. (2009) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2009.11.2/cqiu · Cited by 1,261
Kalaria, R. N., Maestre, G. E., Arizaga, R., Friedland, R. P., Galasko, D., Hall, K., Luchsinger, J. A., Ogunniyi, A., Perry, E. K., Potocnik, F., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70169-8 · Cited by 1,233
Schaefer, E. J., Bongard, V., Beiser, A. S., Lamon-Fava, S., Robins, S. J., Au, R., Tucker, K. L., Kyle, D. J., Wilson, P. W. F., & Wolf, P. A. (2006) · Archives of Neurology · doi:10.1001/archneur.63.11.1545 · Cited by 686
Self-citationSolomon, A., Kivipelto, M., Wolozin, B., Zhou, J., & Whitmer, R. A. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000231980 · Cited by 557
The Role of Adipose Tissue and Adipokines in Obesity-Related Inflammatory Diseases
Balistreri, C. R., Caruso, C., & Candore, G. (2010) · Mediators of Inflammation · doi:10.1155/2010/802078 · Cited by 550
Deckers, K., van Boxtel, M. P. J., Schiepers, O. J. G., de Vugt, M., Muñoz Sánchez, J. L., Anstey, K. J., Brayne, C., Dartigues, J.-F., Engedal, K., Kivipelto, M., et al. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4245 · Cited by 534
Statins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Anstey, K. J., Lipnicki, D. M., & Low, L.-F. (2008) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000310778.20870.ae · Cited by 437
High total cholesterol levels in late life associated with a reduced risk of dementia
Mielke, M. M., Zandi, P. P., Sjögren, M., Gustafson, D., Östling, S., Steen, B., & Skoog, I. (2005) · Neurology · doi:10.1212/01.wnl.0000161870.78572.a5 · Cited by 411
Anstey, K. J., Ashby-Mitchell, K., & Peters, R. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160826 · Cited by 360
“A report examining averageTCover timefrommid- to late-lifeasapredictor of late-life AD in the Framingham study found no associationofTCwithADbut this studydidnotmodel trajectories [52].”
BackgroundMetabolic-cognitive syndrome: A cross-talk between metabolic syndrome and Alzheimer's disease
Frisardi, V., Solfrizzi, V., Seripa, D., Capurso, C., Santamato, A., Sancarlo, D., Vendemiale, G., Pilotto, A., & Panza, F. (2010) · Ageing Research Reviews · doi:10.1016/j.arr.2010.04.007 · Cited by 357
Stroke and the Risk of Alzheimer Disease
Honig, L. S., Tang, M.-X., Albert, S., Costa, R., Luchsinger, J., Manly, J., Stern, Y., & Mayeux, R. (2003) · Archives of Neurology · doi:10.1001/archneur.60.12.1707 · Cited by 343
Cardiovascular disease and Alzheimer's disease: common links
STAMPFER, M. J. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01687.x · Cited by 324
Vascular risk factors, cognitve decline, and dementia
Hanon, O. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s1839 · Cited by 313
Vascular Risk Factors for Incident Alzheimer Disease and Vascular Dementia: The Cache County Study
Hayden, K. M., Zandi, P. P., Lyketsos, C. G., Khachaturian, A. S., Bastian, L. A., Charoonruk, G., Tschanz, J. T., Norton, M. C., Pieper, C. F., Munger, R. G., et al. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213814.43047.86 · Cited by 293
The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE
Guerreiro, R. J., Gustafson, D. R., & Hardy, J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.025 · Cited by 285
“Nevertheless, even within the midlife cholesterol literature, results are conflicting, as some studies have not found high cholesterol to predict later dementia (Kalmijn et al., 2000; Stewart et al., 2007; Tan et al., 2003).”
Xiong, H., Callaghan, D., Jones, A., Walker, D. G., Lue, L.-F., Beach, T. G., Sue, L. I., Woulfe, J., Xu, H., Stanimirovic, D. B., et al. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2007.10.005 · Cited by 280
Juster, R.-P., Bizik, G., Picard, M., Arsenault-Lapierre, G., Sindi, S., Trepanier, L., Marin, M.-F., Wan, N., Sekerovic, Z., Lord, C., et al. (2011) · Development and Psychopathology · doi:10.1017/s0954579411000289 · Cited by 268
“not in all studies (Li et al., 2005; Tan et al., 2003).”
BackgroundBiomarkers of Alzheimer disease in plasma
Irizarry, M. C. (2004) · NeuroRX · doi:10.1602/neurorx.1.2.226 · Cited by 268
Associations Between Serum Cholesterol Levels and Cerebral Amyloidosis
Reed, B., Villeneuve, S., Mack, W., DeCarli, C., Chui, H. C., & Jagust, W. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5390 · Cited by 267
Sierra, S., Ramos, M. C., Molina, P., Esteo, C., Vázquez, J. A., & Burgos, J. S. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101179 · Cited by 248
Dementia, stroke, and vascular risk factors; a review
Sahathevan, R., Brodtmann, A., & Donnan, G. A. (2012) · International Journal of Stroke · doi:10.1111/j.1747-4949.2011.00731.x · Cited by 230
Promoting Successful Cognitive Aging: A Comprehensive Review
Daffner, K. R. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1306 · Cited by 212
Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis
Wood, W. G., Li, L., Müller, W. E., & Eckert, G. P. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12637 · Cited by 194
Dyslipidemia and the Risk of Alzheimer’s Disease
Reitz, C. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0307-3 · Cited by 190
Gene-environment interactions in Alzheimer's disease: A potential path to precision medicine
Eid, A., Mhatre, I., & Richardson, J. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.005 · Cited by 164
Role of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's Disease
Dickstein, D. L., Walsh, J., Brautigam, H., Stockton, S. D., Gandy, S., & Hof, P. R. (2010) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20155 · Cited by 155
Meng, X.-F., Yu, J.-T., Wang, H.-F., Tan, M.-S., Wang, C., Tan, C.-C., & Tan, L. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140954 · Cited by 150
The epidemiologic study of dementia: a life-long quest?
Launer, L. J. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.03.016 · Cited by 142
Cholesterol as a risk factor for Alzheimer's disease - epidemiological evidence
Kivipelto, M., & Solomon, A. (2006) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.2006.00685.x · Cited by 132
Cholesterol, APOE genotype, and Alzheimer disease: An epidemiologic study of Nigerian Yoruba
Hall, K., Murrell, J., Ogunniyi, A., Deeg, M., Baiyewu, O., Gao, S., Gureje, O., Dickens, J., Evans, R., Smith-Gamble, V., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000194507.39504.17 · Cited by 128
Circulating Biomarkers of Cognitive Decline and Dementia
Solfrizzi, V., D'Introno, A., Colacicco, A. M., Capurso, C., Todarello, O., Pellicani, V., Capurso, S. A., Pietrarossa, G., Santamato, V., Capurso, A., et al. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2005.06.015 · Cited by 120
Burgess, B. L., McIsaac, S. A., Naus, K. E., Chan, J. Y., Tansley, G. H. K., Yang, J., Miao, F., Ross, C. J. D., van Eck, M., & Hayden, M. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.06.007 · Cited by 115
HDL from an Alzheimer's disease perspective
Button, E. B., Robert, J., Caffrey, T. M., Fan, J., Zhao, W., & Wellington, C. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000604 · Cited by 114
Cholesterol and Alzheimer’s Disease Risk: A Meta-Meta-Analysis
Sáiz-Vazquez, O., Puente-Martínez, A., Ubillos-Landa, S., Pacheco-Bonrostro, J., & Santabárbara, J. (2020) · Brain Sciences · doi:10.3390/brainsci10060386 · Cited by 135
Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old
Polvikoski, T. M., van Straaten, E. C. W., Barkhof, F., Sulkava, R., Aronen, H. J., Niinistö, L., Oinas, M., Scheltens, P., Erkinjuntti, T., & Kalaria, R. N. (2010) · Neurology · doi:10.1212/wnl.0b013e318200d6f9 · Cited by 88
“This “other” group (n 35) had cases defined as dementia with Lewy bodies (DLB, n 6), DLB with argyrophilic grain disease (AGD) (n 3), AGD with or without hippocampal Abbreviations: AD Alzheimer disease; AGD argyrophilic grain disease; DLB dementia with Lewy bodies; DWMH deep white matter hyperintensities; HS hippocamp…”
BackgroundInfluentialMidlife lipid and glucose levels are associated with Alzheimer's disease
Zhang, X., Tong, T., Chang, A., Ang, T. F. A., Tao, Q., Auerbach, S., Devine, S., Qiu, W. Q., Mez, J., Massaro, J., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12641 · Cited by 65
Peters, R., Xu, Y., Antikainen, R., Beckett, N., Gussekloo, J., Jagger, C., Jukema, J. W., Keinanen-Kiukaanniemi, S., Rydén, L., Skoog, I., et al. (2021) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000519452 · Cited by 51
Zhang, X., Tian, Q., Liu, D., Geng, T., Xu, X., Ge, S., Zheng, D., Wu, L., Song, M., Hou, H., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0822-x · Cited by 51
Mann, K. M. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh199 · Cited by 48
“Other studies, however, have failed to demonstrate a correlation between serum cholesterol levels and AD development (20).”
BackgroundLi, L., Cao, D., Desmond, R., Rahman, A., Lah, J. J., Levey, A. I., & Zamrini, E. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000164271 · Cited by 45
“Furthermore, several observational epidemiological studies examining the association between plasma cholesterol levels and AD have yielded conflicting results [”
ResultCholesterol and Alzheimer's disease
Wolozin, B. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300525 · Cited by 33
Metadata
- Authors
- Tan, Z. S., Seshadri, S., Beiser, A., Wilson, P. W. F., Kiel, D. P., Tocco, M., D'Agostino, R. B., & Wolf, P. A.
- Venue
- Archives of Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2003-05-12
- Volume
- 163
- Issue
- 9
- Pages
- 1053
- ISSN
- 0003-9926
- OpenAlex
- W2049909198
- Cited by
- 280
- References
- 33
- FWCI
- 9.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.